Nanobiotix S.A.

NASDAQ:NBTX

Biotechnology

Healthcare
$26.90 -0.91%

-$0.33 today

Market cap
$1.37B
Beta
0.59
P/E (TTM)
-60.2
EPS (TTM)
-$0.51
52W Low $4.31High $57.14

Volume 0.04M

Average 0.08M

NBTX Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Nanobiotix S.A.NASDAQ: NBTX

Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025

Capital expenditures grows 10.9% year over year

Q4 FY2025 capital expenditures of €396K (cash outflow) rose 10.9% year over year. Over 3 fiscal years it compounded at +81.1% a year.

Context

  • Capital expenditures amounted to 1.8% of revenue in FY2025.
  • Capital expenditures grew in size in 2 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-€396K— QoQ
Last fiscal yearDec 2025
-€546K-35.5% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+10.9%——
1 year-35.5%——
3-year CAGR+81.1%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

EUR · from the cash flow

Latest · FY2025
(546K) EUR
Year-over-year change
+35.5%

Capital Expenditures vs competitors

How NBTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -35.5% is the 5th highest of 8, against a peer median of -26.1%.
  • Capital expenditures amounts to 1.8% of revenue for NBTX, versus a peer median of 2.7%.
NBTX Competitors
Capital Expenditures for NBTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$9.53M USD+87.3%-63.4%5.2%
KURAKura Oncology, Inc.LTM Mar 2026$6.47M USD+852.1%+119.7%9.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$1.26M USD+10391.7%-23.2%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$697.7K USD-26.1%——
NBTXNanobiotix S.A.FY2025€546K EUR-35.5%+81.1%1.8%
TYRATyra Biosciences, Inc.LTM Mar 2026$215K USD-60.3%-36.8%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$187K USD—-6.0%0.1%
PBYIPuma Biotechnology, Inc.LTM Mar 2026$10K USD-91.5%-78.4%0.0%
NVCTNuvectis Pharma, Inc.LTM Mar 2026$0 USD———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 USD———
BDTXBlack Diamond Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%——
Peer median (excluding NBTX) —-26.1%-30.0%2.7%

Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(47M)(57.04M)(39.7M)(68.13M)(23.96M)
Depreciation & Amortization1.56M1.5M1.51M1.62M1.5M
Deferred Income Tax00003K
Stock-Based Compensation3.2M3.17M3.3M4.3M3.54M
Change in Working Capital(4.7M)(606K)(367K)131K(3.4M)
Accounts Receivables62K(101K)(806K)(2.07M)1.85M
Inventory00000
Accounts Payables00000
Other Working Capital(4.76M)(505K)439K2.2M(5.25M)
Other Non-Cash Items17.07M15.87M22.78M42.53M(11.1M)
Operating Cash Flow(29.87M)(37.1M)(12.48M)(19.55M)(33.42M)
Capital Expenditures(228K)(92K)(328K)(846K)(546K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(14K)230K(21K)(109K)(40K)
Investing Cash Flow(242K)138K(349K)(955K)(578K)
Debt Repayment(3.74M)(4.74M)(3.62M)(4.16M)38.19M
Common Stock Issued00001.54M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.44M)(916K)50.39M(980K)(2.31M)
Financing Cash Flow(5.18M)(5.65M)46.77M(5.14M)37.42M
Effect of Forex Changes64K83K(51K)94K(402K)
Net Change in Cash(35.23M)(42.53M)33.9M(25.55M)3.01M
Free Cash Flow(30.1M)(37.2M)(12.8M)(20.4M)(33.97M)

Nanobiotix S.A.

NASDAQ:NBTX

Intrinsic Alpha fair value

Locked

Current Price

$26.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.